Hypomyelinating leukodystrophies constitute a subset of genetic white matter disorders characterized by a primary lack of myelin deposition. Most patients with severe hypomyelination present in infancy or early childhood and develop severe neurological deficits, but the clinical presentation can also be mild with onset of symptoms in adolescence or adulthood. MRI can be used to visualize the process of myelination in detail, and MRI pattern recognition can provide a clinical diagnosis in many patients. Next-generation sequencing provides a definitive diagnosis in 80–90% of patients. Genes associated with hypomyelination include those that encode structural myelin proteins but also many that encode proteins involved in RNA translation and some lysosomal proteins. The precise pathomechanisms remain to be elucidated. Improved understanding of the process of myelination, the metabolic axonal support functions of myelin and the proposed contribution of myelin to CNS plasticity provide possible explanations as to why almost all patients with hypomyelination experience slow clinical decline after a long phase of stability. In this Review, we provide an overview of the hypomyelinating leukodystrophies, the advances in our understanding of myelin biology and of the genes involved in these disorders, and the insights these advances have provided into their clinical presentations and evolution.
Myelination is a finely regulated process that involves interactions between oligodendrocytes, axons, astrocytes and microglia.
Hypomyelinating leukodystrophies are a group of disorders characterized by primary lack of myelin deposition.
Characteristic patterns on brain MRI can guide the diagnosis of hypomyelinating disorders; quantitative MRI techniques can provide measures of white matter myelin content with potential as biomarkers.
The spectrum of clinical severity of hypomyelinating disorders is broad, ranging from mild to severe neurological impairment.
The genetic causes of hypomyelinating leukodystrophies are diverse; the most important groups of affected proteins are structural myelin proteins and proteins involved in cellular processes such as transcription and translation.
Improved understanding of hypomyelinating disorders will guide future treatment strategies, which should not only address myelin deficits but also preserve axonal health.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pouwels, P. J. W. et al. Hypomyelinating leukodystrophies: translational research progress and prospects: leukodystrophies. Ann. Neurol. 76, 5–19 (2014).
Barkovich, A. J. & Deon, S. Reprint of “Hypomyelinating disorders: an MRI approach”. Neurobiol. Dis. 92, 46–54 (2016).
van der Knaap, M. S., Schiffmann, R., Mochel, F. & Wolf, N. I. Diagnosis, prognosis, and treatment of leukodystrophies. Lancet Neurol. 18, 962–972 (2019).
Merzbacher, L. Eine eigenartige familiär-hereditäre Erkrankungsform (Aplasia axialis extracorticalis congenita). Zeitschr. Ges. Neurol. Psych. 3, 1 (1910).
Pelizaeus, F. Ueber eine eigenthümliche form spastischer Lähmung mit Cerebralerscheinungen auf hereditärer Grundlage. Arch. Psychiatr. Nervenkr. 16, 698–710 (1885).
Willard, H. F. & Riordan, J. R. Assignment of the gene for myelin proteolipid protein to the X chromosome: implications for X-linked myelin disorders. Science 230, 940–942 (1985).
Hudson, L. D., Puckett, C., Berndt, J., Chan, J. & Gencic, S. Mutation of the proteolipid protein gene PLP in a human X chromosome-linked myelin disorder. Proc. Natl Acad. Sci. USA 86, 8128–8131 (1989).
Kevelam, S. et al. Update on leukodystrophies: a historical perspective and adapted definition. Neuropediatrics 47, 349–354 (2016).
Chelban, V. et al. Mutations in NKX6-2 cause progressive spastic ataxia and hypomyelination. Am. J. Hum. Genet. 100, 969–977 (2017).
Dorboz, I. et al. Biallelic mutations in the homeodomain of NKX6-2 underlie a severe hypomyelinating leukodystrophy. Brain 140, 2550–2556 (2017).
Simons, C. et al. A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy. Brain 140, 3105–3111 (2017).
Wolf, N. I. et al. Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations. Neurology 83, 1898–1905 (2014).
Czopka, T., Ffrench-Constant, C. & Lyons, D. A. Individual oligodendrocytes have only a few hours in which to generate new myelin sheaths in vivo. Dev. Cell 25, 599–609 (2013). In this study, live imaging in zebrafish was used to show how fast myelin sheaths are generated by oligodendrocytes.
Stadelmann, C., Timmler, S., Barrantes-Freer, A. & Simons, M. Myelin in the central nervous system: structure, function, and pathology. Physiol. Rev. 99, 1381–1431 (2019).
Chang, K.-J., Redmond, S. A. & Chan, J. R. Remodeling myelination: implications for mechanisms of neural plasticity. Nat. Neurosci. 19, 190–197 (2016).
Bakhti, M. et al. Loss of electrostatic cell-surface repulsion mediates myelin membrane adhesion and compaction in the central nervous system. Proc. Natl Acad. Sci. USA 110, 3143–3148 (2013).
Snaidero, N. et al. Antagonistic functions of MBP and CNP establish cytosolic channels in CNS myelin. Cell Rep. 18, 314–320 (2017).
Snaidero, N. & Simons, M. Myelination at a glance. J. Cell Sci. 127, 2999–3004 (2014).
Rasband, M. N. & Peles, E. The nodes of Ranvier: molecular assembly and maintenance. Cold Spring Harb. Perspect. Biol. 8, a020495 (2016).
Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443–448 (2012).
Fünfschilling, U. et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517–521 (2012). Together with Lee et al. (2012), this study emphasizes the supportive function of myelin and long-term axonal integrity.
Nualart-Marti, A., Solsona, C. & Fields, D. R. Gap junction communication in myelinating glia. Biochim. Biophys. Acta 1828, 69–78 (2013).
Saab, A. S., Tzvetanova, I. D. & Nave, K.-A. The role of myelin and oligodendrocytes in axonal energy metabolism. Curr. Opin. Neurobiol. 23, 1065–1072 (2013).
Lappe-Siefke, C. et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 33, 366–374 (2003).
Timmler, S. & Simons, M. Grey matter myelination. Glia 67, 2063–2070 (2019).
Bechler, M. E., Byrne, L. & ffrench-Constant, C. CNS myelin sheath lengths are an intrinsic property of oligodendrocytes. Curr. Biol. 25, 2411–2416 (2015).
Crawford, A. H., Tripathi, R. B., Richardson, W. D. & Franklin, R. J. M. Developmental origin of oligodendrocyte lineage cells determines response to demyelination and susceptibility to age-associated functional decline. Cell Rep. 15, 761–773 (2016).
Dimou, L. & Simons, M. Diversity of oligodendrocytes and their progenitors. Curr. Opin. Neurobiol. 47, 73–79 (2017).
Marques, S. et al. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science 352, 1326–1329 (2016).
Espinosa-Hoyos, D. et al. Engineered 3D-printed artificial axons. Sci. Rep. 8, 478 (2018).
Ong, W. et al. Biomimicking fiber platform with tunable stiffness to study mechanotransduction reveals stiffness enhances oligodendrocyte differentiation but impedes myelination through YAP-dependent regulation. Small 16, 2003656 (2020).
Barres, B. A. & Raff, M. C. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. Nature 361, 258–260 (1993).
Almeida, R. G., Czopka, T., Ffrench-Constant, C. & Lyons, D. A. Individual axons regulate the myelinating potential of single oligodendrocytes in vivo. Development 138, 4443–4450 (2011).
Wake, H. et al. Nonsynaptic junctions on myelinating glia promote preferential myelination of electrically active axons. Nat. Commun. 6, 7844 (2015).
Fernandez-Castaneda, A. & Gaultier, A. Adult oligodendrocyte progenitor cells – multifaceted regulators of the CNS in health and disease. Brain Behav. Immun. 57, 1–7 (2016).
Demerens, C. et al. Induction of myelination in the central nervous system by electrical activity. Proc. Natl Acad. Sci. USA 93, 9887–9892 (1996).
Bengtsson, S. L. et al. Extensive piano practicing has regionally specific effects on white matter development. Nat. Neurosci. 8, 1148–1150 (2005).
Scholz, J., Klein, M. C., Behrens, T. E. J. & Johansen-Berg, H. Training induces changes in white-matter architecture. Nat. Neurosci. 12, 1370–1371 (2009).
Gibson, E. M. et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science 344, 1252304 (2014).
Kato, D. et al. Motor learning requires myelination to reduce asynchrony and spontaneity in neural activity. Glia 68, 193–210 (2019).
Bechler, M. E., Swire, M. & ffrench-Constant, C. Intrinsic and adaptive myelination-A sequential mechanism for smart wiring in the brain. Dev. Neurobiol. 78, 68–79 (2017).
McKinnon, R. D., Waldron, S. & Kiel, M. E. PDGFα-receptor signal strength controls an RTK rheostat that integrates phosphoinositol 3′-kinase and phospholipase C pathways during oligodendrocyte maturation. J. Neurosci. 25, 3499–3508 (2005).
Abrams, C. K. Diseases of connexins expressed in myelinating glia. Neurosci. Lett. 695, 91–99 (2017).
Camargo, N. et al. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biol. 15, e1002605 (2017). This study stresses the role of astrocytes in myelination in providing the necessary lipids for membrane synthesis.
Wlodarczyk, A. et al. A novel microglial subset plays a key role in myelinogenesis in developing brain. EMBO J. 36, 3292–3308 (2017).
Flechsig, P. Developmental (myelogenetic) localisation of the cerebral cortex in the human subject. Lancet 158, 1027–1030 (1901).
Flechsig, P. Anatomie des menschlichen Gehirns und des Rückenmarks auf myelogenetischer Grundlage (Thieme, 1920).
Bercury, K. K. & Macklin, W. B. Dynamics and mechanisms of CNS myelination. Dev. Cell 32, 447–458 (2015).
Patro, N., Naik, A. A. & Patro, I. K. Developmental changes in oligodendrocyte genesis, myelination, and associated behavioral dysfunction in a rat model of intra-generational protein malnutrition. Mol. Neurobiol. 56, 595–610 (2018).
Prado, E. L. & Dewey, K. G. Nutrition and brain development in early life. Nutr. Rev. 72, 267–284 (2014).
Horstmann, M. et al. Infantile cobalamin deficiency with cerebral lactate accumulation and sustained choline depletion. Neuropediatrics 34, 261–264 (2003).
Taskesen, M., Yaramis, A., Pirinccioglu, A. G. & Ekici, F. Cranial magnetic resonance imaging findings of nutritional vitamin B12 deficiency in 15 hypotonic infants. Eur. J. Paediatr. Neurol. 16, 266–270 (2012).
Steinfeld, R. et al. Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am. J. Hum. Genet. 85, 354–363 (2009).
Kobayashi, Y. et al. Severe leukoencephalopathy with cortical involvement and peripheral neuropathy due to FOLR1 deficiency. Brain Dev. 39, 266–270 (2016).
Barres, B. A., Lazar, M. A. & Raff, M. C. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 120, 1097–1108 (1994).
Lee, J. Y. & Petratos, S. Thyroid hormone signaling in oligodendrocytes: from extracellular transport to intracellular signal. Mol. Neurobiol. 53, 6568–6583 (2016).
Tonduti, D. et al. MCT8 deficiency: extrapyramidal symptoms and delayed myelination as prominent features. J. Child Neurol. 28, 795–800 (2012).
Holland, B. A., Haas, D. K., Norman, D., Brant-Zawadzki, M. & Newton, T. H. MRI of normal brain maturation. Am. J. Neuroradiol. 7, 201–208 (1986).
van der Knaap, M. S. & Valk, J. MR imaging of the various stages of normal myelination during the first year of life. Neuroradiology 31, 459–470 (1990).
Barkovich, A. J. Concepts of myelin and myelination in neuroradiology. Am. J. Neuroradiol. 21, 1099–1109 (2000).
Barkovich, A. J. & Maroldo, T. V. Magnetic resonance imaging of normal and abnormal brain development. Top. Magnetic Reson. Imaging 5, 96–122 (1993).
Paus, T. et al. Maturation of white matter in the human brain: a review of magnetic resonance studies. Brain Res. Bull. 54, 255–266 (2011).
Branson, H. M. Normal myelination: a practical pictorial review. Neuroimaging Clin. N. Am. 23, 183–195 (2013).
Steenweg, M. E. et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain 133, 2971–2982 (2010). In this study, MRI pattern recognition, the use of which was established for non-hypomyelinating leukodystrophies, is systematically used for hypomyelinating leukodystrophies.
Steenweg, M. E. et al. Novel hypomyelinating leukoencephalopathy affecting early myelinating structures. Arch. Neurol. 69, 125–128 (2012).
van der Knaap, M. S. et al. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. Am. J. Neuroradiol. 23, 1466–1474 (2002).
Kevelam, S. H. et al. Altered PLP1 splicing causes hypomyelination of early myelinating structures. Ann. Clin. Transl Neurol. 2, 648–661 (2015).
Simons, C. et al. A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am. J. Hum. Genet. 92, 767–773 (2013).
Cayami, F. K. et al. 4H leukodystrophy: lessons from 3 T imaging. Neuropediatrics 49, 112–117 (2017).
Mendes, M. I. et al. Bi-allelic mutations in EPRS, encoding the glutamyl-prolyl-aminoacyl-tRNA synthetase, cause a hypomyelinating leukodystrophy. Am. J. Hum. Genet. 102, 676–684 (2018).
Mendes, M. I. et al. RARS1-related hypomyelinating leukodystrophy: expanding the spectrum. Ann. Clin. Transl Neurol. 7, 83–93 (2019).
Wolf, N. I. et al. Leukoencephalopathy with ataxia, hypodontia, and hypomyelination. Neurology 64, 1461–1464 (2005).
Taft, R. J. et al. Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and leg spasticity. Am. J. Hum. Genet. 92, 774–780 (2013).
Harting, I. et al. Oculodentodigital dysplasia: a hypomyelinating leukodystrophy with a characteristic MRI pattern of brain stem involvement. Am. J. Neuroradiol. 40, 903–907 (2019).
Morell, P. & Quarles, R. in Basic Neurochemistry: Molecular, Cellular, and Medical Aspects (ed. Siegel, G.) 69–94 (Raven, 1999).
Norton, W. & Cammer, W. in Myelin (ed. Morell, P.) 147–195 (Springer, 1984).
Dobbing, J. & Sands, J. Quantitative growth and development of human brain. Arch. Dis. Child. 48, 757–767 (1973).
Koenig, S. H., Brown, R. D., Spiller, M. & Lundbom, N. Relaxometry of brain: why white matter appears bright in MRI. Magn. Reson. Med. 14, 482–495 (1990).
Koenig, S. H. Cholesterol of myelin is the determinant of gray-white contrast in MRI of brain. Magn. Reson. Med. 20, 285–291 (1991).
Harkins, K. D. et al. The microstructural correlates of T1 in white matter. Magn. Reson. Med. 75, 1341–1345 (2015).
van der Voorn, J. P. et al. Childhood white matter disorders: quantitative MR imaging and spectroscopy. Radiology 241, 510–517 (2006).
Depienne, C. et al. Brain white matter oedema due to ClC-2 chloride channel deficiency: an observational analytical study. Lancet Neurol. 12, 659–668 (2013).
van der, Knaap, M. S., Barth, P. G., Vrensen, G. F. J. M. & Valk, J. Histopathology of an infantile-onset spongiform leukoencephalopathy with a discrepantly mild clinical course. Acta Neuropathol. 92, 206–212 (1996).
Kolind, S. H., Mädler, B., Fischer, S., Li, D. K. B. & MacKay, A. L. Myelin water imaging: implementation and development at 3.0 T and comparison to 1.5 T measurements. Magn. Reson. Med. 62, 106–115 (2009).
Dvorak, A. V. et al. Multi-spin echo T 2 relaxation imaging with compressed sensing (METRICS) for rapid myelin water imaging. Magn. Reson. Med. 84, 1264–1279 (2020).
Björk, M., Zachariah, D., Kullberg, J. & Stoica, P. A multicomponent T 2 relaxometry algorithm for myelin water imaging of the brain: multicomponent T 2 relaxometry. Magn. Reson. Med. 75, 390–402 (2015).
Billiet, T. et al. Age-related microstructural differences quantified using myelin water imaging and advanced diffusion MRI. Neurobiol. Aging 36, 2107–2121 (2015).
Morris, S. R. et al. Brain myelin water fraction and diffusion tensor imaging atlases for 9–10 year-old children. J. Neuroimaging 30, 150–160 (2020).
Liu, H. et al. Myelin water atlas: a template for myelin distribution in the brain. J. Neuroimaging 29, 699–706 (2019).
Chen, H. S.-M., Holmes, N., Liu, J., Tetzlaff, W. & Kozlowski, P. Validating myelin water imaging with transmission electron microscopy in a rat spinal cord injury model. Neuroimage 153, 122–130 (2017).
Deoni, S. C. L., Dean, D. C., O’Muircheartaigh, J., Dirks, H. & Jerskey, B. A. Investigating white matter development in infancy and early childhood using myelin water fraction and relaxation time mapping. Neuroimage 63, 1038–1053 (2012). In this study, myelination was monitored with myelin water imaging, providing an excellent method to follow normal brain development.
Geeraert, B. L., Lebel, R. M. & Lebel, C. A multiparametric analysis of white matter maturation during late childhood and adolescence. Hum. Brain Mapp. 40, 4345–4356 (2019).
Zhang, J., Kolind, S. H., Laule, C. & MacKay, A. L. How does magnetization transfer influence mcDESPOT results? Magn. Reson. Med. 74, 1327–1335 (2015).
Wolff, S. D. & Balaban, R. S. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn. Reson. Med. 10, 135–144 (1989).
Stanisz, G. J., Kecojevic, A., Bronskill, M. J. & Henkelman, R. M. Characterizing white matter with magnetization transfer and T2. Magn. Reson. Med. 42, 1128–1136 (1999).
Dreha-Kulaczewski, S. F. et al. Assessment of myelination in hypomyelinating disorders by quantitative MRI. J. Magn. Reson. Imaging 36, 1329–1338 (2012).
Steenweg, M. E. et al. Quantitative MRI in hypomyelinating disorders: correlation with motor handicap. Neurology 87, 752–758 (2016).
van Waesberghe, J. H. et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. 46, 747–754 (1999).
Blezer, E. L. A., Bauer, J., Brok, H. P. M., Nicolay, K. & ’t Hart, B. A. Quantitative MRI-pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis. NMR Biomed. 20, 90–103 (2007).
Basser, P. J. & Pierpaoli, C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. 213, 560–570 (1996).
Zhang, H., Schneider, T., Wheeler-Kingshott, C. A. & Alexander, D. C. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 61, 1000–1016 (2012).
Campbell, J. S. W. et al. Promise and pitfalls of g-ratio estimation with MRI. Neuroimage 182, 80–96 (2017).
Jung, W. et al. Whole brain g-ratio mapping using myelin water imaging (MWI) and neurite orientation dispersion and density imaging (NODDI). Neuroimage 182, 379–388 (2018).
Dean, D. C. et al. Mapping an index of the myelin g-ratio in infants using magnetic resonance imaging. Neuroimage 132, 225–237 (2016).
Klasen, T. & Faber, C. Assessment of the myelin water fraction in rodent spinal cord using T2-prepared ultrashort echo time MRI. MAGMA 29, 875–884 (2016).
Cercignani, M. & Bouyagoub, S. Brain microstructure by multi-modal MRI: is the whole greater than the sum of its parts? Neuroimage 182, 117–127 (2018).
Spader, H. S. et al. Advances in myelin imaging with potential clinical application to pediatric imaging. Neurosurg. Focus 34, E9 (2013).
Groeschel, S. et al. Assessing white matter microstructure in brain regions with different myelin architecture using MRI. PLoS ONE 11, e0167274 (2016).
Geeraert, B. L. et al. A comparison of inhomogeneous magnetization transfer, myelin volume fraction, and diffusion tensor imaging measures in healthy children. Neuroimage 182, 343–350 (2018).
Hobson, G. M. & Garbern, J. Y. Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders. Semin. Neurol. 32, 62–67 (2012).
Syrbe, S. et al. Delineating SPTAN1 associated phenotypes: from isolated epilepsy to encephalopathy with progressive brain atrophy. Brain 140, 2322–2336 (2017).
Wolf, N. I. et al. Mutations in RARS cause hypomyelination. Ann. Neurol. 76, 134–139 (2014).
Curiel, J. et al. TUBB4A mutations result in specific neuronal and oligodendrocytic defects that closely match clinically distinct phenotypes. Hum. Mol. Genet. 26, 4506–4518 (2017).
Chelban, V. et al. Genetic and phenotypic characterization of NKX6-2-related spastic ataxia and hypomyelination. Eur. J. Neurol. 27, 334–342 (2020).
Baldi, C. et al. Expanding the clinical and genetic spectra of NKX6-2-related disorder. Clin. Genet. 93, 1087–1092 (2018).
Orthmann-Murphy, J. L. et al. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain 132, 426–438 (2008).
Svenstrup, K. et al. Hereditary spastic paraplegia caused by the PLP1 “rumpshaker mutation”. J. Neurol. Neurosurg. Psychiatry 81, 666–672 (2009).
Wolf, N. I. et al. DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder. Neurology 84, 226–230 (2015).
Sarret, C. et al. Novel neuronal proteolipid protein isoforms encoded by the human myelin proteolipid protein 1 gene. Neuroscience 166, 522–538 (2010).
Lüders, K. A., Patzig, J., Simons, M., Nave, K.-A. & Werner, H. B. Genetic dissection of oligodendroglial and neuronal Plp1 function in a novel mouse model of spastic paraplegia type 2. Glia 65, 1762–1776 (2017).
Sarret, C. et al. Time-course of myelination and atrophy on cerebral imaging in 35 patients with PLP1-related disorders. Dev. Med. Child Neurol. 58, 706–713 (2016).
Bos, S. V. den et al. 4H leukodystrophy: a brain magnetic resonance imaging scoring system. Neuropediatrics 48, 152–160 (2017).
Garbern, J. Y. et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125, 551–561 (2002). This study demonstrated axonal degeneration in a primary myelin disorder.
Sima, A. A. F. et al. Neuronal loss in Pelizaeus-Merzbacher disease differs in various mutations of the proteolipid protein 1. Acta Neuropathol. 118, 531–539 (2009).
Uhlenberg, B. et al. Mutations in the gene encoding gap junction protein α12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am. J. Hum. Genet. 75, 251–260 (2004). In this study, the first new gene involved in a disease resembling PMD was identified.
Pingault, V. et al. Peripheral neuropathy with hypomyelination, chronic intestinal pseudo-obstruction and deafness: a developmental “neural crest syndrome” related to a SOX10 mutation. Ann. Neurol. 48, 671–676 (2000).
Biancheri, R. et al. Hypomyelination and congenital cataract: broadening the clinical phenotype. Arch. Neurol. 68, 1191–1194 (2011).
Garbern, J. Y. et al. Peripheral neuropathy caused by proteolipid protein gene mutations. Ann. NY Acad. Sci. 883, 351–365 (1999).
Wolff, A. et al. Rare dental peculiarities associated with the hypomyelinating leukoencephalopathy 4H syndrome/ADDH. Pediatr. Dent. 32, 386–392 (2010).
Saint-Val, L. et al. GJA1 variants cause spastic paraplegia associated with cerebral hypomyelination. Am. J. Neuroradiol. 40, 788–791 (2019).
Ghoumid, J. et al. Cerebellar hypoplasia with endosteal sclerosis is a POLR3-related disorder. Eur. J. Hum. Genet. 25, 1011–1014 (2017).
Miyake, N. et al. X-linked hypomyelination with spondylometaphyseal dysplasia (H-SMD) associated with mutations in AIFM1. Neurogenetics 18, 185–194 (2017).
Pelletier, F. et al. Endocrine and growth abnormalities in 4H leukodystrophy caused by variants in POLR3A, POLR3B, and POLR1C. J. Clin. Endocrinol. Metabolism https://doi.org/10.1210/clinem/dgaa700 (2020).
Laukka, J. J. et al. Neuroradiologic correlates of clinical disability and progression in the X-linked leukodystrophy Pelizaeus-Merzbacher disease. J. Neurol. Sci. 335, 75–81 (2013).
Sumida, K. et al. The magnetic resonance imaging spectrum of Pelizaeus-Merzbacher disease: a multicenter study of 19 patients. Brain Dev. 38, 571–580 (2016).
Trofatter, J. A., Dlouhy, S. R., DeMyer, W., Conneally, P. M. & Hodes, M. E. Pelizaeus-Merzbacher disease: tight linkage to proteolipid protein gene exon variant. Proc. Natl Acad. Sci. USA 86, 9427–9430 (1989).
Paznekas, W. A. et al. Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. Am. J. Hum. Genet. 72, 408–418 (2003).
Taube, J. et al. PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing. Hum. Mol. Genet. 23, 5464–5478 (2014). This study identified deep intronic PLP1 mutations in patients with a subform of PMD, leading to an imbalance of PLP1–DM20 splicing.
Sistermans, E. A., Coo, R. F., de, Wijs, I. J. D. & Oost, B. A. V. Duplication of the proteolipid protein gene is the major cause of Pelizaeus-Merzbacher disease. Neurology 50, 1749–1754 (1998).
Wolf, N. I. et al. Three or more copies of the proteolipid protein gene PLP1 cause severe Pelizaeus-Merzbacher disease. Brain 128, 743–751 (2005).
Grossi, S. et al. Molecular genetic analysis of the PLP1 gene in 38 families with PLP1-related disorders: identification and functional characterization of 11 novel PLP1 mutations. Orphanet J. Rare Dis. 6, 40 (2011).
Elitt, M. S. et al. Chemical screening identifies enhancers of mutant oligodendrocyte survival and unmasks a distinct pathological phase in Pelizaeus-Merzbacher disease. Stem Cell Rep. 11, 711–726 (2018).
Numasawa-Kuroiwa, Y. et al. Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes. Stem Cell Rep. 2, 648–661 (2014).
Al-Abdi, L. et al. CNP deficiency causes severe hypomyelinating leukodystrophy in humans. Hum. Genet. 139, 615–622 (2020).
Fernandez-Valle, C., Gorman, D., Gomez, A. M. & Bunge, M. B. Actin plays a role in both changes in cell shape and gene-expression associated with Schwann cell myelination. J. Neurosci. 17, 241–250 (1997).
Basu, R. & Sarma, J. D. Connexin 43/47 channels are important for astrocyte/oligodendrocyte cross-talk in myelination and demyelination. J. Biosci. 43, 1055–1068 (2018).
Kamasawa, N. et al. Connexin-47 and connexin-32 in gap junctions of oligodendrocyte somata, myelin sheaths, paranodal loops and Schmidt-Lanterman incisures: implications for ionic homeostasis and potassium siphoning. Neuroscience 136, 65–86 (2005).
Vejar, S., Oyarzún, J. E., Retamal, M. A., Ortiz, F. C. & Orellana, J. A. Connexin and Pannexin-based channels in oligodendrocytes: implications in brain health and disease. Front. Cell Neurosci. 13, 3 (2019).
Meyer, N. et al. Oligodendrocytes in the mouse corpus callosum maintain axonal function by delivery of glucose. Cell Rep. 22, 2383–2394 (2018).
Duncan, I. D. et al. A mutation in the Tubb4a gene leads to microtubule accumulation with hypomyelination and demyelination: Tubb4a mutation. Ann. Neurol. 81, 690–702 (2017).
Segel, M. et al. Niche stiffness underlies the ageing of central nervous system progenitor cells. Nature 573, 130–134 (2019).
Yan, H. et al. Heterozygous variants in the mechanosensitive ion channel TMEM63A result in transient hypomyelination during infancy. Am. J. Hum. Genet. 105, 996–1004 (2019).
Lee, S., Chong, S. Y. C., Tuck, S. J., Corey, J. M. & Chan, J. R. A rapid and reproducible assay for modeling myelination by oligodendrocytes using engineered nanofibers. Nat. Protoc. 8, 771–782 (2013).
Tétreault, M. et al. Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy. Am. J. Hum. Genet. 89, 652–655 (2011).
Bernard, G. et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. Am. J. Hum. Genet. 89, 415–423 (2011).
Saitsu, H. et al. Mutations in POLR3A and POLR3B encoding RNA polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy. Am. J. Hum. Genet. 89, 644–651 (2011).
Thiffault, I. et al. Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III. Nat. Commun. 6, 7623 (2015).
Dorboz, I. et al. Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation. Neurol. Genet. 4, e289 (2018).
Feinstein, M. et al. Pelizaeus-Merzbacher-like disease caused by AIMP1/p43 homozygous mutation. Am. J. Hum. Genet. 87, 820–828 (2010).
Inoue, K., Tanabe, Y. & Lupski, J. R. Myelin deficiencies in both the central and the peripheral nervous systems associated with a SOX10 mutation. Ann. Neurol. 46, 313–318 (1999).
Elmaleh-Bergès, M. et al. Spectrum of temporal bone abnormalities in patients with Waardenburg syndrome and SOX10 mutations. Am. J. Neuroradiol. 34, 1257–1263 (2012).
Ito, Y. et al. Lysosomal dysfunction in TMEM106B hypomyelinating leukodystrophy. Neurol. Genet. 4, e288 (2018).
Zhou, X. et al. Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. Brain 143, 1905–1919 (2020).
Feng, T. et al. A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination. Brain 143, 2255–2271 (2020). Together with Zhou et al. (2020), this study demonstrated the role of TMEM106B in trafficking and myelination.
Edvardson, S. et al. Hypomyelination and developmental delay associated with VPS11 mutation in Ashkenazi-Jewish patients. J. Med. Genet. 52, 749–753 (2015).
Hörtnagel, K. et al. The second report of a new hypomyelinating disease due to a defect in the VPS11 gene discloses a massive lysosomal involvement. J. Inherit. Metab. Dis. 39, 849–857 (2016).
Barmherzig, R. et al. A new patient with intermediate severe Salla disease with hypomyelination: a literature review for Salla disease. Pediatr. Neurol. 74, 87–91.e2 (2017).
Koch, T. K., Schmidt, K. A., Wagstaff, J. E., Ng, W. G. & Packman, S. Neurologic complications in galactosemia. Pediatr. Neurol. 8, 217–220 (1992).
Zara, F. et al. Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract. Nat. Genet. 38, 1111–1113 (2006).
Baskin, J. M. et al. The leukodystrophy protein FAM126A (hyccin) regulates PtdIns(4)P synthesis at the plasma membrane. Nat. Cell Biol. 18, 132–138 (2016).
Magen, D. et al. Mitochondrial Hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am. J. Hum. Genet. 83, 30–42 (2008).
Hamilton, E. M. C. et al. UFM1 founder mutation in the Roma population causes recessive variant of H-ABC. Neurology 89, 1821–1828 (2017).
Jaeken, J. et al. 3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis. J. Inherit. Metab. Dis. 19, 223–226 (1996).
Damseh, N. et al. Mutations in SLC1A4, encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination. J. Med. Genet. 52, 541–547 (2015).
Escobar, J. D. O. & Dueñas, B. P. Treatable inborn errors of metabolism due to membrane vitamin transporters deficiency. Sem. Pediatr. Neurol. 23, 341–350 (2016).
Sase, S. et al. TUBB4A mutations result in both glial and neuronal degeneration in an H-ABC leukodystrophy mouse model. eLife 9, e52986 (2020).
Meyer, E. et al. Promoter mutation is a common variant in GJC2-associated Pelizaeus–Merzbacher-like disease. Mol. Genet. Metab. 104, 637–643 (2011).
Combes, P. et al. Relevance of GJC2 promoter mutation in Pelizaeus-Merzbacher-like disease. Ann. Neurol. 71, 146–148 (2011).
Helman, G. et al. Genome sequencing in persistently unsolved white matter disorders. Ann. Clin. Transl Neurol. 7, 144–152 (2020).
Nave, K.-A. Neurological mouse mutants and the genes of myelin. J. Neurosci. Res. 38, 607–612 (1994).
Al-Saktawi, K. et al. Genetic background determines phenotypic severity of the Plp rumpshaker mutation. J. Neurosci. Res. 72, 12–24 (2003).
Fanarraga, M. L. et al. Rumpshaker: an X-linked mutation affecting CNS myelination. A study of the female heterozygote. Neuropathol. Appl. Neurobiol. 17, 323–334 (1991).
Molineaux, S. M., Engh, H., de Ferra, F., Hudson, L. & Lazzarini, R. A. Recombination within the myelin basic protein gene created the dysmyelinating shiverer mouse mutation. Proc. Natl Acad. Sci. USA 83, 7542–7546 (1986).
Vaurs-Barriere, C. et al. Golli-MBP copy number analysis by FISH, QMPSF and MAPH in 195 patients with hypomyelinating leukodystrophies. Ann. Hum. Genet. 70, 66–77 (2006).
Arai-Ichinoi, N. et al. Genetic heterogeneity in 26 infants with a hypomyelinating leukodystrophy. Hum. Genet. 135, 89–98 (2015).
Garbern, J. et al. Evidence for neuroaxonal injury in patients with proteolipid gene mutations. Neurology 57, 1938–1939 (2001).
Marques, S. et al. Transcriptional convergence of oligodendrocyte lineage progenitors during development. Dev. Cell 46, 504–517.e7 (2018).
Tantzer, S., Sperle, K., Kenaley, K., Taube, J. & Hobson, G. M. Morpholino antisense oligomers as a potential therapeutic option for the correction of alternative splicing in PMD, SPG2, and HEMS. Mol. Ther. Nucleic Acids 12, 420–432 (2018).
Li, H. et al. Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA. JCI Insight 4, e125052 (2019).
Elitt, M. S. et al. Suppression of proteolipid protein rescues Pelizaeus–Merzbacher disease. Nature 585, 397–403 (2020). Together with Li et al. (2019), this study produced promising results with respect to suppression of elevated PLP1 expression in models of PMD.
Windrem, M. S. et al. Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell 2, 553–565 (2008). In this study, transplantation of glial progenitor cells was used for the first time to rescue a leukodystrophy mouse model.
Osorio, M. J. et al. Concise review: stem cell-based treatment of Pelizaeus-Merzbacher disease. Stem Cell 35, 311–315 (2016).
Gupta, N. et al. Long-term safety, immunologic response, and imaging outcomes following neural stem cell transplantation for Pelizaeus-Merzbacher disease. Stem Cell Rep. 13, 254–261 (2019).
Gupta, N. et al. Neural stem cell engraftment and myelination in the human brain. Sci. Transl Med. 4, 155ra137 (2012). This study was the first trial of transplantation of neural stem cells into brain tissue of four children with PMD.
Goldman, S. A., Schanz, S. & Windrem, M. S. Stem cell-based strategies for treating pediatric disorders of myelin. Hum. Mol. Genet. 17, R76–R83 (2008).
Wolf, N. I. et al. Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction. Ann. Clin. Transl Neur. 7, 169–180 (2020).
Stumpf, S. K. et al. Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus–Merzbacher disease. Acta Neuropathol. 138, 147–161 (2019).
Saher, G. & Stumpf, S. K. Cholesterol in myelin biogenesis and hypomyelinating disorders. Biochim. Biophys. Acta 1851, 1083–1094 (2015).
Saher, G. et al. Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. Nat. Med. 18, 1130–1135 (2012).
Nobuta, H. et al. Oligodendrocyte death in Pelizaeus-Merzbacher disease is rescued by iron chelation. Cell Stem Cell 25, 531–541.e6 (2019).
M.S.v.d.K. and N.I.W. are members of the European Reference Network for Rare Neurological Disorders (ERN-RND), project ID 739510. C.ff.-C. is a recipient of a Wellcome Trust Investigator award.
N.I.W. is a member of advisory boards for Ionis, Passage Bio and Takeda Shire.
Peer review information
Nature Reviews Neurology thanks K. Inoue, D. Rodriguez and R. Schiffmann for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wolf, N.I., ffrench-Constant, C. & van der Knaap, M.S. Hypomyelinating leukodystrophies — unravelling myelin biology. Nat Rev Neurol 17, 88–103 (2021). https://doi.org/10.1038/s41582-020-00432-1
Acta Neuropathologica Communications (2021)
Spinal cord involvement and paroxysmal events in “Infantile Onset Transient Hypomyelination” due to TMEM63A mutation
Journal of Human Genetics (2021)